These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

110 related items for PubMed ID: 9581839

  • 21. Identification of a ras oncogene peptide that contains both CD4(+) and CD8(+) T cell epitopes in a nested configuration and elicits both T cell subset responses by peptide or DNA immunization.
    Bristol JA, Orsini C, Lindinger P, Thalhamer J, Abrams SI.
    Cell Immunol; 2000 Nov 01; 205(2):73-83. PubMed ID: 11104579
    [Abstract] [Full Text] [Related]

  • 22. The immunologic function of 1B2+ double negative (CD4-CD8-) T cells in the 2C transgenic mouse.
    Margenthaler JA, Flye MW.
    J Surg Res; 2005 Jun 15; 126(2):160-6. PubMed ID: 15919414
    [Abstract] [Full Text] [Related]

  • 23. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
    Ojima T, Iwahashi M, Nakamura M, Matsuda K, Naka T, Nakamori M, Ueda K, Ishida K, Yamaue H.
    Int J Oncol; 2006 Apr 15; 28(4):947-53. PubMed ID: 16525645
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Anti-4-1BB monoclonal antibody enhances rejection of large tumor burden by promoting survival but not clonal expansion of tumor-specific CD8+ T cells.
    May KF, Chen L, Zheng P, Liu Y.
    Cancer Res; 2002 Jun 15; 62(12):3459-65. PubMed ID: 12067989
    [Abstract] [Full Text] [Related]

  • 26. Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen.
    Saha A, Chatterjee SK, Foon KA, Celis E, Bhattacharya-Chatterjee M.
    Cancer Res; 2007 Mar 15; 67(6):2881-92. PubMed ID: 17363612
    [Abstract] [Full Text] [Related]

  • 27. Mouse homologue of a novel human oncofetal antigen, glypican-3, evokes T-cell-mediated tumor rejection without autoimmune reactions in mice.
    Nakatsura T, Komori H, Kubo T, Yoshitake Y, Senju S, Katagiri T, Furukawa Y, Ogawa M, Nakamura Y, Nishimura Y.
    Clin Cancer Res; 2004 Dec 15; 10(24):8630-40. PubMed ID: 15623647
    [Abstract] [Full Text] [Related]

  • 28. Cytotoxic T cell responses to DNA vaccination: dependence on antigen presentation via class II MHC.
    Maecker HT, Umetsu DT, DeKruyff RH, Levy S.
    J Immunol; 1998 Dec 15; 161(12):6532-6. PubMed ID: 9862678
    [Abstract] [Full Text] [Related]

  • 29. B7.2-Ig fusion proteins enhance IL-4-dependent differentiation of tumor-sensitized CD8+ cytotoxic T lymphocyte precursors.
    Hiraoka S, Takeuchi N, Bian Y, Nakahara H, Kogo M, Dunussi-Joannopoulos K, Wolf S, Ono S, Fujiwara H.
    Int Immunol; 2005 Aug 15; 17(8):1071-9. PubMed ID: 16027141
    [Abstract] [Full Text] [Related]

  • 30. Th2-type CD4+ cells neither enhance nor suppress antitumor CTL activity in a mouse tumor model.
    Fernando GJ, Stewart TJ, Tindle RW, Frazer IH.
    J Immunol; 1998 Sep 01; 161(5):2421-7. PubMed ID: 9725239
    [Abstract] [Full Text] [Related]

  • 31. Vaccination with dendritic cells pulsed in vitro with tumor antigen conjugated to cholera toxin efficiently induces specific tumoricidal CD8+ cytotoxic lymphocytes dependent on cyclic AMP activation of dendritic cells.
    Sun JB, Eriksson K, Li BL, Lindblad M, Azem J, Holmgren J.
    Clin Immunol; 2004 Jul 01; 112(1):35-44. PubMed ID: 15207780
    [Abstract] [Full Text] [Related]

  • 32. Induction of tumor-specific in vivo protective immunity by immunization with tumor antigen-pulsed antigen-presenting cells.
    Hamaoka T, Shimizu J, Suda T, Fujiwara H.
    Princess Takamatsu Symp; 1988 Jul 01; 19():265-75. PubMed ID: 3269360
    [Abstract] [Full Text] [Related]

  • 33. Phase I trial of a MART-1 peptide vaccine with incomplete Freund's adjuvant for resected high-risk melanoma.
    Wang F, Bade E, Kuniyoshi C, Spears L, Jeffery G, Marty V, Groshen S, Weber J.
    Clin Cancer Res; 1999 Oct 01; 5(10):2756-65. PubMed ID: 10537339
    [Abstract] [Full Text] [Related]

  • 34. Induction of tumor-specific in vivo protective immunity by immunization with tumor antigen-pulsed antigen-presenting cells.
    Shimizu J, Suda T, Yoshioka T, Kosugi A, Fujiwara H, Hamaoka T.
    J Immunol; 1989 Feb 01; 142(3):1053-9. PubMed ID: 2464022
    [Abstract] [Full Text] [Related]

  • 35. Lymphotactin gene-modified bone marrow dendritic cells act as more potent adjuvants for peptide delivery to induce specific antitumor immunity.
    Cao X, Zhang W, He L, Xie Z, Ma S, Tao Q, Yu Y, Hamada H, Wang J.
    J Immunol; 1998 Dec 01; 161(11):6238-44. PubMed ID: 9834111
    [Abstract] [Full Text] [Related]

  • 36. Enhancement by IL-12 of the cytolytic T lymphocyte (CTL) response of mice immunized with tumor-specific peptides in an adjuvant containing QS21 and MPL.
    Silla S, Fallarino F, Boon T, Uyttenhove C.
    Eur Cytokine Netw; 1999 Jun 01; 10(2):181-90. PubMed ID: 10400824
    [Abstract] [Full Text] [Related]

  • 37. Identification of a unique antigen peptide pRL1 on BALB/c RL male 1 leukemia recognized by cytotoxic T lymphocytes and its relation to the Akt oncogene.
    Uenaka A, Ono T, Akisawa T, Wada H, Yasuda T, Nakayama E.
    J Exp Med; 1994 Nov 01; 180(5):1599-607. PubMed ID: 7964448
    [Abstract] [Full Text] [Related]

  • 38. [Cytotoxic and blocking antibodies in the sera and eluates from spleen cells of mice with Rauscher leukemia following a different course].
    Ter-Grigorov VS, Dzagurov SG, Shevelev BI.
    Biull Eksp Biol Med; 1975 Feb 01; 79(2):76-80. PubMed ID: 48386
    [No Abstract] [Full Text] [Related]

  • 39. Rejection antigen peptides on BALB/c RL male 1 leukemia recognized by cytotoxic T lymphocytes: derivation from the normally untranslated 5' region of the c-akt proto-oncogene activated by long terminal repeat.
    Wada H, Matsuo M, Uenaka A, Shimbara N, Shimizu K, Nakayama E.
    Cancer Res; 1995 Nov 01; 55(21):4780-3. PubMed ID: 7585504
    [Abstract] [Full Text] [Related]

  • 40. The involvement of antigen-presenting cells and suppressor cells in the ultraviolet radiation-induced inhibition of secondary cytotoxic T cell sensitization.
    Jensen PJ.
    J Immunol; 1983 May 01; 130(5):2071-4. PubMed ID: 6220078
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.